pharmaceutical preparations having controlled release of isradipine or darodipine

摘要

Case 100-6717 A controlled release formulation for oral administration comprising - an active substance chosen from the group of Pindolol and a 4-(2,1, 3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester, - a pharmaceutically acceptable hydrophilic swellable substance and containing optionally a pharmaceutically acceptable inert fatty material in addition. The formulation has an excellent bioavailability and practically no food interaction after administration. 3700/KD/AB